# Amicus Curiae Brief — Gonzales v. Oregon

> Briefs, arguments, decisions, and more.

URL: https://www.frixlaw.com/law-library/documents/brief%3Amicro_IA40385016_0051%3A34

## Record

- **Collection:** Supreme Court brief
- **Document type:** Amicus Curiae Brief
- **Published:** January 1, 2006
- **Citation:** 546 U.S. 243

## Text

rr
No. 04-623 , 2 18 20065

;

IN THE

Supreme Court of the United States

ALBERTO GONZALES,
Attorney General, et al.
Petitioners,
v.

STATE OF OREGON, et al.,
Respondents.

ON WRIT OF CERTIORARI TO THE
UNITED STATES COURT OF APPEALS
FOR THE NINTH CIRCUIT

BRIEF FOR PROFESSORS OF LAW
RICHARD BRIFFAULT, WILLIAM N. ESKRIDGE, JR.,
PHILIP P. FRICKEY, ELIZABETH GARRETT,
JERRY L. MASHAW, EDWARD RUBIN,
DAVID L. SHAPIRO, PETER L. STRAUSS,

AND ERNEST A. YOUNG AS AMICI CURIAE
SUPPORTING RESPONDENTS

DAVID W. OGDEN
Counsel of Record
PAUL R.Q. WOLFSON
DAVID S. MENDEL
DANIELLE SPINELLI
HEATHER ELLIOTT
NORA FREEMAN ENGSTROM
WILMER CUTLER PICKERING
HALE AND DORR LLP
2445 M Street, N.W.
Washington, DC 20037
(202) 663-6000

—_—_———SS a

TABLE OF AUTHORITIES
INTEREST OF AMICI

lL.
Il.

ITI.

IV.

V.

TABLE OF CONTENTS

THE DIRECTIVE IMPROPERLY PREEMPTS
STATE LAW AND ALTERS THE TRADITIONAL
FEDERAL-STATE BALANCE IN THE REGULA-

TION OF MEDICAL PRACTICE.......cccccccscosssecocecesesesees

A. A Federal Statute Is Presumed Not To
Preempt State Law Regulating The Prac-

ERE RECS Ga sree Oe ED

B. A Federal Statute Is Presumed Not To AI-

ter The Federal-State Balance........c.ccccccces0....-.

C. The CSA Does Not Authorize The Attor-
ney General To Set Uniform Standards Of

Medical Practice For The States ......................

THE RULE OF LENITY COUNSELS AGAINST
THE ATTORNEY GENERAL’S INTERPRETATION

Ge ee Te crvinsecininisencienercnspreansennitepnssitisinsiaiscniainminiaaasiens

THE CSA SHOULD NoT BE READ To PRE-
CLUDE DEMOCRATIC DEBATE AND EXPLORA-
TION OF DIFFERENT APPROACHES BY THE
STATES ON THE QUESTION OF PHYSICIAN-

REET A AN

THE ATTORNEY GENERAL’S DIRECTIVE

WARRANTS NO DEFERENCE ......ccccssscscscesesececseseeeeees
CONCLUSION

SOOO EEE EE THEE EEE EEE E HEHEHE HERE OREO EES

SOOO HEHEHE EEE EEE TEESE EEE EE EEE EEE EEEESESEEEEEE ESSERE EEE EEEEOEES

ii
TABLE OF AUTHORITIES
CASES
Page(s)
Auer v. Robbins, 519 U.S. 452 (1997)........ccccccccccsssesesessssereceees 28
Babbitt v. Sweet Home Chapter of Communities for

a Greater Oregon, 515 U.S. 687 (1995) c.ccccccccccsccccseseceeeees 22

BFP vy. Resolution Trust Corp., 511 U.S. 531
(BBE). .cccaseecesssevesvesenresentundssasiieiamsieniselasanaannannnn 10, 11, 17
Chevron U.S.A. Inc. v. Natural Resources Defense

Council, Inc., 467 U.S. 837 (1984).........cccccsscessosssesesesseees 26
Christensen v. Harris County, 529 U.S. 576 (2000)... 27
Cleveland v. United States, 531 U.S. 12 (2000) ...cccccccccccccceces 21
Crandon v. United States, 494 U.S. 152 (1990) oo... 20, 21
FDA v. Brown & Williamson Tobacco Corp.,

SED US. 159 CRBCG) ...cxrssssessscensassiensendinesiuaisamaaaaaea 29
Gibbons v. Ogden, 22 U.S. (9 Wheat.) 1 (1824) voccccccccceseeeeees 8
Gonzales v. Raich, 125 S. Ct. 2195 (2005).....c.cccccccccsessecesseceeeeee 5
Gregory v. Ashcroft, 501 U.S. 452 (1991) ....cccccccccsceceeeseees 10, 11
Helvering v. Stuart, 327 U.S. 154 (1942) v...ccccccscscccesesceecesees 17
Hillsborough County v. Automated Medical

Laboratories, Inc., 471 U.S. 707 (1985) ..cccccccscccesceseecescees 8
INS vy. Cardoza-Fonseca, 480 U.S, 421 (1987) ....ccccccccscecesseees 28
Kent v. Dulles, 357 U.S. 116 (1958) ........cccccccccosscsscsscescescesseeses 29
Leocal v. Ashcroft, 125 S. Ct. 377 (2004) ....cccccccscssscssseseseseseees 21
MCI Telecommunications Corp. v. AT&T, 512 U.S.

| 26, 29
Martin v. OSHRC, 499 U.S. 144 (1991) ...c.ccccccccssscsseleccsesesceeee 28
McNally v. United States, 483 U.S. 350 (1987) cece. 20, 21
Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996).....cccccccccesee 3, 8, 10
Mississippi Band of Choctaw Indians v. Holyfield,

480 U 3. 3B (2BBB) .n.c:cecccoseiccsessnecessussninensensnaaiaiennnnnnne 17
New State Ice Co. v. Liebmann, 285 U.S. 262 (1932)........ 4, 24
Pegram v. Herdrich, 530 U.S. 211 (2000) ....cccccccccseseseseseseeeeeee 8
Rice v. Santa Fe Elevator Corp., 331 U.S. 218

(1'96'7)....ccccscccceeeveseensnnessesnenenserisannsteiselsiiiinsssinnnnnninnnnnnnEEE 8
Rogers v. Tennessee, 532 U.S. 451 (2001) ....ccccccccceccecsesceseceeces 20

Rush Prudential HMO, Inc. v. Moran, 536 U.S. 355
(GIDE)... -cccecerssesceessvsesennecnssnsnennssnennnenaninnnnnnnnnnnnnnEEE 8

TABLE OF AUTHORITIES—Continued
Page(s)
Skidmore v. Swift & Co., 323 U.S. 134 (1944)... 26, 27
Solid Waste Agency of Northern Cook County v.
United States Army Corps of Engineers,
EE 10, 30
Thomas Jefferson University v. Shalala, 512 U.S.
CO EEE 28, 29
Touby v. United States, 500 U.S. 160 (1991)... 5, 6, 27
United States v. Bass, 404 U.S. 336 (1971)... 10, 20, 21
United States v. Kozminski, 487 U.S. 931 (1988).............. 4,19
United States v. Mead Corp., 533 U.S. 218 (2001)..... 26, 27, 28
United States v. Moore, 422 U.S. 122 (1975).............. 15, 17, 18
United States v. Oakland Cannabis Buyers’
Cooperative, 532 U.S. 483 (2001)........ccccceseserereeeeeesees 17, 18
United States v. Rosenberg, 515 F.2d 190 (9th Cir.
PEE LAA 18
United States v. Thompson/Center Arms, Co.,
a 21
Washington v. Glucksberg, 521 U.S. 702 (1997)............ passim
Webb v. United States, 249 U.S. 96 (1919) .....ccccccccccccecseeeeeneee 15
Whalen v. United States, 445 U.S. 684 (1980)........ccccccccceseseee 20
Whitman v. American Trucking Associations,
Ee 29
STATUTES
Controlled Substances Act
ee 3, 6, 12, 15, 19
a 5, 6, 19, 28
a 5, 18, 19
a cre 5, 12, 13
ae 3, 6
CC 3, 5
Ee 12, 18
ee 14
Ee 6
66 Fed. Reg. 56,607 (Nov. 9, 2001)..........ccccccccccsesesesssesesesssececeees 7

iv

TABLE OF AUTHORITIES—Continued

Page(s)
Oregon Death With Dignity Act
ED 7
a, Eh, Cet OP Ga hiccenitcciscnsnnnehiesiesinstinietinneitiabiiasiiitiaiaae 7
OR NG i 7, 25
Rs Rs As a) UII ccrrssssscinibsnssinnsisiniinindiliitsiataeeeiaen 25
Ss Rs eit) II ccrinticseenessiencsistetinnintateiisstasiniinataatainen 7
Pub. L. No. 91-513, 84 Stat. 1236 (1970) ..........cccccccsceceseseeeeees 13
LEGISLATIVE MATERIALS
H.R. Rep. No. 91-1444 (1970) .............cccccsssessessesesesneees 13, 14, 16
S. Rep. No. 98-225 (1984), reprinted in 1984
eats Oe nrstensnnenitinniennntimnentitaemintasteimness 13, 14
BE.0E. SBBD, BOG Corny, (12GB I) aeccccecccccsesscsscscscessscsssscesssensescesoee 16
H.R. 4006, 105th Cong. (1998).............-ccecssscscsesesesssserssesesesseees 16
OTHER AUTHORITIES
Letter from Attorney General Reno to Rep. Henry
en I Ts TIE cnicresinsereensintersninsiniilicisintbitnierbticieeantaatateaintaies 7

Manning, John F., Constitutional Structure and
Judicial Deference to Agency Interpretations
of Agency Rules, 96 Colum. L. Rev. 612 (1996)............. 29
Oregon Department of Human Services, Seventh
Annual Report on Oregon’s Death With
nD SRN ee teircceenenertusitiainieienanniainindiiaaentataass 9, 25

Supreme Court of the United States

No. 04-623

ALBERTO GONZALES,
Attorney General, et al.
Petitioners,
v.

STATE OF OREGON, et al.,
Respondents.

ON WRIT OF CERTIORARI TO THE
UNITED STATES COURT OF APPEALS
FOR THE NINTH CIRCUIT

Amici curiae Richard Priffault, William N. Eskridge,
Jr., Philip P. Frickey, Elizabeth Garrett, Jerry L. Mashaw,
Edward Rubin, David L. Shapiro, Peter L. Strauss, and
Ernest A. Young respectfully submit this brief supporting
affirmance of the judgment below. '

INTEREST OF AMICI

Amici are law professors who teach and write from
range of perspectives on topics that include statutory inter-
pretation, administrative law, legislative process, and feder-
alism and who therefore have a professional interest in the
proper application and development of law in these areas.

' No counsel for a party authored this brief in whole or in part, and
no person or entity other than amici and their counsel made any monetary
contribution toward the preparation or submission of this brief. Letters
indicating the parties’ consent to the filing of this brief have been submit-
ted to the Clerk.

2

Richard Briffault, the Joseph P. Chamberlain Professor
of Legislation and Director of the Legislative Drafting Re-
search Fund at Columbia Law School, is the co-author of a
leading casebook on state and local government law and has
published widely on issues of federalism. William N.
Eskridge, Jr., the John A. Garver Professor of Jurispru-
dence at Yale Law School, has written numerous scholarly
articles on legislation and statutory interpretation and is the
co-author, with Professors Frickey and Garrett, of the lead-
ing casebook and student treatise on legislation. Philip P.
Frickey, the Richard W. Jennings Professor of Law at the
University of California, Berkeley School of Law (Boalt
Hall), has written extensively on statutory interpretation
and the legislative process. Elizabeth Garrett, the Sydney
M. Irmas Professor of Public Interest Law, Legal Ethics,
Political Science, and Policy, Planning and Development at
the University of Southern California, is the Director of the
USC-Caltech Center for the Study of Law and Politics and
has publishe i widely in the areas of statutory interpretation
and lawmaking. Jerry L. Mashaw, the Sterling Professor of
Law at Yale Law School, is the author of numerous scholarly
articles on administrative law and legislation and has co-
authored a leading casebook on administrative law. Edward
Rubin, the Dean and John Wade-Kent Syverud Professor of
Law at Vanderbilt University Law School, has written ex-
tensively in the fields of administrative law and statutory
interpretation. David L. Shapiro, the William Nelson
Cromwell Professor of Law at Harvard Law School, has
published widely in the areas of federalism, administrative
law, and statutory interpretation. Peter L. Strauss, the
Betts Professor of Law at Columbia Law School, is the co-
author of a leading administrative law casebook and the au-
thor of numerous scholarly articles on administrative law
and statutory interpretation. Ernest A. Young, the Judge
Benjamin Harrison Powell Professor in Law at the Univer-
sity of Texas School of Law, has written extensively on is-
sues of federalism and constitutional and statutory interpre-
tation. :

3

While this case implicates profound and difficult ques-
tions regarding end-of-life care, it is at bottom a case about
determining congressional intent: this Court must deter-
mine whether the Controlled Substances Act (CSA) makes it
a crime, or grants the Attorney General the power to make
it a crime, for physicians to prescribe controlled substances
as authorized by the Oregon Death With Dignity Act
(ODWDA). Amici respectfully seek to provide the Court
with a discussion of principles of statutory construction and
administrative law that bear on that question.

INTRODUCTION AND SUMMARY OF ARGUMENT

This case undoubtedly raises important issues relating
to the ability of terminally ill patients to obtain the assis-
tance of physicians in ending their lives. What should not be
obscured, however, is that this case fundamentally presents
a question of statutory interpretation. The threshold—and,
in our view, dispositive—question before this Court is
whether the Attorney General’s Directive is a legitimate
reading of the CSA’s requirement that doctors prescribing
controlled substances must act “in the course of professional
practice.” 21 U.S.C. § 802(21); see id. §§ 829, 841(a).

Two fundamental principles of statutory construction
are relevant to that inquiry. First, the Directive’s reading of
the CSA contravenes the presumption that, absent a clear
statement, a federal statute will not be read to preempt
state law or significantly to alter the federal-state balance.
Here, the Directive effectively precludes Oregon residents
from exercising the option made available to them by Ore-
gon law, preempting Oregon’s choice expressly to permit the
prescription of controlled substances for that purpose. And
it does so by intruding into an area—the regulation of medi-
cal practice—that is “primarily, and historically, a matter of
local concern.” Medtronic, Inc. v. Lohr, 518 U.S. 470, 475
(1996) (citation omitted). But the CSA—which was enacted
for the very different purpose of addressing illicit drug traf-
ficking and abuse—does not set uniform standards of medi-
cal practice for the States or authorize the Attorney General
to do so. To the contrary, the CSA expressly provides that

q

it does not preempt state law unless that law presents a
positive conflict with its terms; the relevant provisions of the
CSA expressly turn in part on state law; and the CSA grants
the Attorney General no authority to make scientific or
medical decisions. The text, structure, and purpose of the
CSA make plain that Congress did not intend to displace the
States’ traditional authority to regulate medical practice
within their borders. ”

Second, the Attorney General’s aggressive reading of
the CSA criminalizes conduct that the CSA does not plainly
prohibit. It is a “time-honored interpretive guideline,” how-
ever, “that uncertainty concerning the ambit of criminal
statutes should be resolved in favor of lenity.” United States
v. Kozminski, 487 U.S. 931, 952 (1988). The rule of lenity
ensures that Congress—the most democratically account-
able branch—has carefully considered whether to create a
federal crime and has made a conscious judgment to do so.
Because the CSA does not clearly make state-authorized
physician-assisted suicide a crime or give the Attorney Gen-
eral the power to do so, the rule of lenity strongly counsels
against the Directive’s interpretation.

Both of these canons ultimately stem from respect for
the democratic process in our federal system and are in-
tended to ensure that difficult and important social ques-
tions—particularly those that affect vital state interests—
are resolved through that process. They are thus particu-
larly relevant to this case, in which Oregon voters have de-
cided to permit their State to “serve as a laboratory,” im-
plementing the “novel social ... experiment[]” of regulated
and controlled physician-assisted suicide “without risk to the
rest of the country.” New State Ice Co. v. Liebmann, 285
U.S. 262, 311 (1932) (Brandeis, J., dissenting). As this Court
has observed, “[t)]hroughout the Nation, Americans are en-
gaged in an earnest and profound debate about the morality,
legality, and practicality of physician-assisted suicide.”
Washington v. Glucksberg, 521 U.S. 702, 735 (1997). The Di-
rective would bring that “earnest and profound debate” to
an end. Because there is no evidence Congress intended

5

that result, this Court should reject the Directive, permit-
ting the people of the States to continue democratic debate
and exploration of different approaches to end-of-life care.

Finally, because the Directive is not a permissible read-
ing of the CSA, this Court need not reach the Attorney Gen-
eral’s claim that the Directive is entitled to deference. Were
it to reach that question, however, basic tenets of adminis-
trative law mandate that the Directive’s novel and expan-
sive construction of the CSA—an informal interpretive rule
issued without notice and comment and purnorting to re-
solve a morally and politically fraught question on which the
Attorney General has no expertise—should receive no def-
erence. The Attorney General’s unpersuasive attempt to
overreach his authority under the CSA should be rejected.

ARGUMENT
I. THE STATUTORY AND REGULATORY SCHEME

The CSA, enacted in 1970, makes it a crime to possess,
distribute, or dispense a controlled substance “{e]xcept as
authorized” by the statute. 21 U.S.C. § 841(a)(1). As this
Court recently explained: “The main objectives of the CSA
were to conquer drug abuse and to control the legitimate
and illegitimate traffic in controlled substances. Congress
was particularly concerned with the need to prevent the di-
version of drugs from legitimate to illicit channels.” Gonza-
les v. Raich, 125 8. Ct. 2195, 2203 (2005) (footnotes omitted).

To that end, the CSA classifies controlled substances
into five “schedules.” 21 U.S.C. § 812. Substances with “no
currently accepted medical use in treatment in the United
States” are placed in Schedule I, id. § 812(b)(1)(B), and may
be dispensed only for extremely limited research purposes,
see id. § 823(f). By contrast, substances with “a currently
accepted medical use in treatment in the United States” are
placed in Schedules II-V, id. § 812(b)(2)-(5), and may be dis-
pensed by physicians to patients as authorized by the CSA.

Under the CSA, the Attorney General may decide that

a substance should be controlled and place it on a particular
schedule. See id. § 811(a); Touwby v. United States, 500 U.S.

6

160, 162-163 (1991). Before doing so, however, he must ob-
tain a scientific and medical evaluation of the drug from the
Secretary of Health and Human Services, and he may not
control the drug if the Secretary recommends against it. 21
U.S.C. § 811(b). Indeed, the Secretary’s recommendations
are “binding” as to all “scientific and medical matters.” /d.
The Attorney General has no authority to make medical and
scientific determinations relevant to scheduling decisions.’

The CSA provides that substances on Schedules II-V
may be dispensed by practitioners who are federally regis-
tered to do so, see id. § 823(f), and are acting “in the course
of professional practice,” id. § 802(21) (defining “practitio-
ner” as one who acts “in the course of professional practice”);
see id. § 829 (providing that “practitioners” may prescribe or
dispense controlled substances).

In 1971, through notice-and-comment rulemaking, the
Attorney General promulgated a regulation implementing
the CSA’s “course of professional practice” requirement.
The regulation provides: “A prescription for a controlled
substance, to be effective, must be issued for a legitimate
medical purpose by an individuai practitioner acting in
the usual course of his professional practice.” 21 C.F.R.
§ 1306.04. A prescription not “issued ... in the usual course
of ... professional treatment” is invalid, and writing such a
prescription is a crime. Jd.’

In 1994, by ballot initiative, the people of Oregon
adopted the ODWDA, which provides that “[a}n adult who is
capable, is a resident of Oregon, and has been determined
[by two physicians] to be suffering from a terminal disease,
and who has voluntarily expressed his or her wish to die,
may make a written request for medication for the purpose

>The Attorney General must also consider eight specified factors
and comply with the notice-and-comment provisions of the Administrative
Procedure Act before adding a drug to a schedule. See 21 U.S.C. § 811(a),
(c); Touby, 500 U.S. at 162-163.

Amici do not question the validity of the 1971 regulation.

7

of ending his or her life in a humane and dignified manner.”
Or. Rev. Stat. § 127.805(1). The statute expressly authorizes
physicians to prescribe such medication if its requirements
are met, see id. § 127.815, and provides that physicians who
do so shall not “be subject to civil or criminal liability or pro-
fessional disciplinary action,” id. § 127.885(1).

After passege of the ODWDA, various persons, includ-
ing then-Senator John Ashcroft, sought an opinion from
then-Attorney General Janet Reno as to whether a doctor
who prescribed controlled substances under the ODOWDA
would violate the CSA. After considering the views of par-
ties on both sides of the question, Attorney General Reno
concluded: “There is no evidence that Congress, in the CSA,
intended to displace the states as the primary regulators of
the medical profession, or to override a state’s determination
as to what constitutes legitimate medical practice .... [T]he
CSA does not authorize DEA to prosecute, or to revoke the
DEA registration of, a physician who has assisted in a sui-
cide in compliance with Oregon law.” Letter irom Attorney
General Reno to Rep. Henry Hyde at 4-5 (June 5, 1998).

In 2001, Ashcroft, now himself the Attorney General,
reversed course by issuing the Directive, an informal inter-
pretive rule issued without notice and comment or any con-
sultation with Oregon and other interested parties. The Di-
rective provides that “assisting suicide is not a ‘legitimate
medical purpose’ within the meaning of 21 C.F.R. § 1306.04”
and therefore “that prescribing, dispensing, or administering
federally controlled substances to assist suicide violates” the
CSA, “regardless of whether state law authorizes or permits
such conduct.” 66 Fed. Reg. 56,607 (Nov. 9, 2001).

Il. THE DIRECTIVE IMPROPERLY PREEMPTS STATE LAW
AND ALTERS THE TRADITIONAL FEDERAL-STATE BAL-
ANCE IN THE REGULATION OF MEDICAL PRACTICE

It is a well-settled principle—deriving from the most
basic aspects of our federal system—that if Congress in-
tends to preempt state law or otherwise displace state au-
thority in an arena traditionally regulated by the States, it

8

will say so in plain terms. No such plain statement appears
in the CSA. Rather, the text and structure of the statute
make clear that Congress intended to leave the substantive
regulation of the practice of medicine—including the resolu-
tion of hotly debated questions of medical ethics, such as ap-
propriate measures for end-of-life care—where it has always
primarily been, with the States. The Directive’s contrary
interpretation therefore cannot be sustained.

A. A Federal Statute Is Presumed Not To Preempt
State Law Regulating The Practice Of Medicine

The States’ primary authority to regulate the practice
of medicine has been well-settled since the early days of the
Republic. See Gibbons v. Ogden, 22 U.S. (9 Wheat.) 1, 203
(1824) (the police powers of the States include “[{i]nspection
laws, quarantine laws, [and] health laws of every descrip-
tion”). This Court has often reiterated that “regulation of
health and safety matters is primarily, and historically, a
matter of local concern.” Hillsborough County v. Auto-
mated Med. Labs., Inc., 471 U.S. 707, 719 (1985); see also
Medtronic, Inc. v. Lohr, 518 U.S. 470, 475 (1996). Indeed,
establishing “standards of reasonable medical care” is a
“quintessentially state-law” function. Rush Prudential
HMO, Inc. v. Moran, 536 U.S. 355, 387 (2002).

This Court has often held that where “Congress [has]
legislated ... in a field which the States have traditionally
occupied ... we start with the assumption that the historic
police powers of the States were not to be superseded by the
Federal Act unless that was the clear and manifest purpose
of Congress.” Rice v. Santa Fe Elevator Corp., 331 U.S. 218,
230 (1947). “[I}n the field of health care, a subject of tradi-
tional state regulation, there is no ... preemption without
clear manifestation of congressional purpose.” Pegram v.
Herdrich, 530 U.S. 211, 237 (2000); see also, e.g., Medtronic,
518 U.S. at 485.

The Attorney General’s Directive would preempt cen-
tral provisions of the ODWDA by making it a crime for doc-
tors to prescribe controlled substances in the manner ex-

9

pressly authorized by the Oregon law. The Attorney Gen-
eral argues (Br. 44) that no preemption occurs because Ore-
gon physicians remain free to “dispense substances other
than those regulated under the CSA to hasten their patients’
deaths.” But every prescription written thus far under the
ODWDA has been for barbiturates—Schedule II controlled
substances under the CSA.’ The Attorney General points to
no way in which Oregon physicians could safely and effec-
tively accomplish the purposes of the ODWDA without pre-
scribing federally controlled substances. In any event, even
if the Directive might leave intact some highly theoretical
applications of the ODWDA, it precludes most of the stat-
ute’s applications. The Attorney General’s argument is
therefore at best a quibble over the scope, not the fact, of
preemption.

The Attorney General also contends (Br. 43) that the
Directive does not preempt Oregon law because the
ODWDA is still valid insofar as it exempts physicians from
state prosecution. But this wholly misapprehends the effect
of the Directive. The ODWDA expressly authorizes doctors
to prescribe medications, including federally. controlled sub-
stances, in accordance with its terms. Under the Supremacy
Clause, however, Oregon cannot authorize Oregon doctors
to take action that is prohibited by federal law. Thus, if the
Directive validly stated federal law, its prohibition would
preempt the contrary provisions of the ODWDA.

The Attorney General’s contention that “States are not
free to displace the federal-law duty to comply with the
CSA” (Br. 44) merely begs the question. Clearly Oregon law
cannot “preempt” the CSA. But the question here is the
meaning of the CSA—and that meaning must be determined
against the backdrop principle that Congress does not
lightly intrude into areas traditionally regulated by the
States. Nor can the Attorney General evade this principle

* See Oregon Dep’t of Human Services, Seventh Annual Report on
Oregon’s Death With Dignity Act 14 (2005).

10

with the claim that the Directive merely “frustrates the
purposes of Oregon’s voter initiative” (Br. 43). Respect for
the States’ sovereignty, and their primary authority over
the regulation of medicine within their borders, requires
that federal statutes be interpreted so as not to frustrate
state law, absent a clear indication that Congress so in-
tended. As shown below, see infra Part I1.C, no such indica-
tion appears in the CSA.

B. A Federal Statute Is Presumed Not To Alter The
Federal-State Balance

The basic interpretive principle that statutes are con-
strued to respect the States’ status as “independent sover-
eigns in our federal system,” Medtronic, 518 U.S. at 485, ex-
tends beyond the context of preemption. Although “Con-
gress may legislate in areas traditionally regulated by the
States,” this is “a power that we must assume Congress does
not exercise lightly.” Gregory v. Ashcroft, 501 U.S. 452, 460
(1991). Thus, “unless Congress conveys its purpose clearly,
it will not be deemed to have significantly changed the fed-
eral-state balance” by making law in an area historically re-
served to the States. United States v. Bass, 404 U.S. 336,
349 (1971); see also, e.g., Solid Waste Agency of N. Cook
County v. United States Army Corps of Eng’rs, 531 U.S.
159, 173 (2001); BFP v. Resolution Trust Corp., 511 U.S. 531,
544 (1994). This clear statement rule “assures that [Con-
gress] has in fact faced, and intended to bring into issue, the
critical issues involved” when it legislates in an area tradi-
tionally reserved to the States. Bass, 404 U.S. at 349.

The Attorney General mistakenly contends (Br. 38-39)
that the Directive does not implicate this rule because it
does not reach to the core of state sovereignty. Although
Gregory v. Ashcroft applied the rule to avoid federal inter-
ference with state law establishing the qualifications of state
judges, see 501 U.S. at 460, the rule’s application is not lim-
ited to such circumstances. Rather, as both Bass and BFP
make clear, the rule applies whenever a federal statute
“would mark a major inroad into a domain traditionally left
to the States.” Bass, 404 U.S. at 339 (applying rule to hold

11

that federal criminal statute did not criminalize conduct al-
ready made a crime by state law). “Federal statutes imping-
ing upon important state interests ‘cannot ... be construed
without regard to the implications of our dual system of gov-
ernment.” BFP, 511 U.S. at 544 (citation omitted). Con-
gress may override state law in an area traditionally regu-
lated by the States when it does so unambiguously; “[{bJut
where the intent to override is doubtful, our federal system
demands deference to long-established traditions of state
regulation.” Jd. at 546.

The question in BFP was the meaning of the phrase
“reasonably equivalent value” in the Bankruptcy Code’s
fraudulent transfer provisions. This Court held that, when
property is sold at a foreclosure sale conducted in accor-
dance with state law, whatever price is thereby obtained is
“reasonably equivalent value.” See BFP, 511 U.S. at 545.
The Court reasoned that interpreting “reasonably equiva-
lent value,” as the court of appeals had done, to “specify a
federal ‘reasonable’ foreclosure-sale price,” id. at 540, would
cast « cloud on the title of much foreclosed property, frus-
trating state law in an area historically the province of the
States. See id. at 544. Because the statute evinced no “clear
and manifest” intent “[tJo displace traditional state regula-
tion in such a manner,” it would not be read to do so. Jd.

This case presents very similar concerns. The Attorney
General’s interpretation of the CSA directly impinges on an
important state interest in an area traditionally regulated by
the States. The purpose of the clear statement rule is to
preserve a “federalist structure of joint sovereigns ... that
will be more sensitive to the diverse needs of a heterogene-
ous society” and that “increases opportunity for citizen in-
volvement in democratic processes; [and] allows for more
innovation and experimentation in government.” Gregory,
501 U.S. at 458. That purpose is plainly implicated here.
The Directive not only intrudes upon a realm hist vrically the
province of the States, but goes much further—it purports
to resolve complex moral questions regarding end-of-life
care, questions that are the subject of “an earnest and pro-

12

found debate” among the people of the States. Washington
v. Glucksberg, 521 U.S. 702, 735 (1997). Before adopting
such an interpretation of a statute whose primary purpose
was to address quite different questions, it is appropriate to
take great care to ensure that Congress intended that result.

C. The CSA Does Not Authorize The Attorney Gen-
eral To Set Uniform Standards Of Medical Prac-
tice For The States

1. The CSA contains no indication—clear or other-
wise—that Congress intended to grant the Attorney Gen-
eral the power to set uniform federal standards of medical
practice for the States. To the contrary, the CSA expressly
states that it should not be construed to override state law
unless the conflict between the text of the CSA and state
law is plain. See 21 U.S.C. § 903 (“No provision of this sub-
chapter shall be construed as indicating an intent on the part
of the Congress to occupy the field . . . to the exclusion of any
State law on the same subject matter which would otherwise
be within the authority of the State, unless there is a posi-
tive conflict between that provision ... and that State law so
that the two cannot consistently stand together.”). There is
no such positive conflict here.

Indeed, from the beginning, the CSA has looked to state
law to determine which persons are “practitioners” acting
“in the course of professional practice” and are thus eligible
for federal registration to dispense controlled substances.
The very definition of “practitioner” under the CSA turns in
part on state law, providing that a “practitioner” includes “a
physician ... licensed ... by the United States or the juris-
diction in which he practices ... to ... dispense ... a con-
trolled substance in the course of professional practice.” 21
U.S.C. § 802(21) (emphasis added). That provision clearly
contemplates that state law will inform the contours of “the
course of professional practice” for purposes of the CSA.

The CSA’s registration provisions also expressly recog-
nize the primacy of state law in determining the circum-
stances under which controlled substances may properly be
dispensed. The statute provides that “(t]he Attorney Gen-

13

eral shall register practitioners . .. to dispense . . . controlled
substances in Schedule II, III, IV, or V, if the applicant is
authorized to dispense ... controlled substances under the
laws of the State in which he practices.” Id. § 823(f) (empha-
sis added). Under the CSA as originally enacted, registra-
tion was “a matter of right where the individual or firm is
engaged in activities involving these drugs which are
authorized or permitted under State law.” H.R. Rep. No.
91-1444, pt. 1, at 23 (1970). The Attorney General was
authorized to revoke or suspend a registration only if the
registrant had materially falsified his application, had been
convicted of a felony relating to controlled substances, or
“had his State license or registration suspended, revoked, or
denied by competent State authority.” Pub. L. No. 91-513,
§ 304(a), 84 Stat. 1236, 1255 (1970).

In 1984, Coagress amended the CSA’s registration pro-
visions in order to address “the problem of diversion of dan-
gerous drugs” into the hands of drug abusers, against which
“many States [had been] unable to take effective or prompt
action.”” As amended, the statute continues to provide that
practitioners licensed by the State in which they practice are
presumptively entitled to registration. See 21 U.S.C.
§ 823(f). The Attorney General may deny, suspend, or re-
voke a registration of a state-licensed practitioner if doing so
is in “the public interest.” /d. In determining the “public
interest,” however, the Attorney General must consider five
factors, the first of which is “[t]he recommendation of the
appropriate State licensing board or professional discipli-
nary authority.” Jd. § 823(f)(1).° The statute itself thus

*S. Rep. No. 98-225, at 266 (1983); see also id. at 266-267 (citing, as a
key reason for the amendment, “delays in obtaining conviction” under
state law of doctors who have “abused their authority to dispense con-
trolled substances”).

° Two other factors also turn in part on state law—“|t|he applicant's
conviction record under Federal or State laws relating to the manufac-
ture, distribution, or dispensing of controlled substances,” id. § 823(f)(3),
and “{cjompliance with applicable State, Federal, or local laws relating to
controlled substances,” id. § 823(f)(4).

14

makes clear that the Attorney General is still expected to
defer to the views of state licensing autnorities, and that
Congress did not intend to override the States’ primary au-
thority to regulate medical practice.’ Congress’s objective in
amending the statute was much narrower: to ensure that
doctors acting as drug dealers would not retain their federal
registration merely because state authorities failed ade-
quately to enforce state law.

The statute makes clear that, had Congress intended to
impose a uniform federal standard for medical practice, it
knew how to do so. The CSA does expressly contemplate
uniform federal standards in one narrow area: the treat-
ment of narcotics addiction. See 42 U.S.C. § 290bb-2a (“The
Secretary of Health and Human Services, after consultation
with the Attorney General . . . shall determine the appropri-
ate methods of professional practice in the medical treat-
ment of the narcotic addiction of various classes of narcotic
addicts ....” ). Notably, however, the authority to devise
this standard was given to the Secretary, not the Attorney
General, whom Congress has consistently declined to en-
trust with medical decisions. See id.” Congress’s explicit
decision to permit the Secretary to create uniform federal
standards in this narrow area, combined with its more gen-
eral reluctance to displace state regulation of medical prac-

’ The legislative history confirms what the text makes plain: “the
amendment would continue to give deference to the opinions of State li-
censing authorities, since their recommendations are the first of the fac-
tors to be considered with respect to practitioner applications.” S. Rep.
No. 98-225, at 267.

*The Attorney General's reliance on these provisions (Br. 32-33) is
accordingly misplaced; they demonstrate not that Congress intended to
give the Attorney General the power to set uniform standards of medical
practice for the States in all contexts, but rather that it intended to give
the Secretary the power to do so in one specific narrow context. See H.R.
Rep. No. 91-1444, at 15 (expressing “concern|| about the appropriateness
of having Federal officials determine the appropriate method of the prac-
tice of medicine,” but opining that it was necessary to set uniform federal
standards in that specific area in order to address doctors’ unwillingness
to accept drug addicts as patients).

15

tice, show that Congress did not empower the Attorney
General to override state regulation of medical practice in
other areas.

2. In the face of this powerful evidence that Congress
did not intend to give the Attorney General the power to
displace the States’ long-standing regulatory authority over
the practice of medicine, the Attorney General first argues
(Br. 18-19) that the statute’s “course of professional prac-
tice” requirement, 21 U.S.C. § 802(21), itself clearly prohibits
the prescription of controlled substances for the purpose of
physician-assisted suicide. But that phrase, on its face, is
certainly broad enough to encompass any medical practice
expressly authorized by state law. Indeed, this Court has
interpreted the “course of professional practice” standard to
mean only that, when prescribing controlled substances, a
doctor must be acting in the service of what he believes to be
the good of his patients, rather than some other goal, such as
personal gain. That is, a doctor must be acting as a doctor
and not as a drug dealer. Thus, in United States v. Moore,
this Court held that a doctor violated the CSA by prescrib-
ing controlled substances “not for legitimate purposes, but
‘primarily for the profits to be derived therefrom,” 423 U.S.
122, 135 (1975), and thus “act[ing] as a large-scale ‘pusher’
not as a physician,” id. at 143.”

Lacking any more persuasive evidence in the text of the
statute, the Attorney General falls back on the argument
(Br. 18-19) that dictionary definitions of the word “medicine”
exclude physician-assisted suicide as a “legitimate medical
purpose”—the phrase employed by the regulation. But, as

* Similarly, this Court’s decision in Webb v. United States, 249 U.S.
96 (1919)—relied on by the Attorney General (Br. 19)—held that a doctor
who sold morphine to addicts solely to assist them in satisfying their ad-
diction was not acting in the course of professional practice within the
meaning of the Harrison Act, the predecessor to the CSA. See 249 U.S. at
97. Neither case remotely suggests that the CSA intended to go beyond
criminalizing the illicit distribution of drugs for profit to supersede the
States’ authority to define the practice of medicine.

16

the Attorney General himself acknowledges (Br. 17 n.6), the
regulation’s “legitimate medical purpose” standard merely
restates the statute’s “course of professional practice” re-
quirement. It does not—and indeed could not—criminalize
conduct not reached by the terms of the CSA itself.

In any event, the Attorney General’s wooden recitation
of dictionary definitions does not support his view that the
CSA empowers him to make physician-assisted suicide a
crime. The definitions of “medicine” that he cites—which
include “alleviation” of “disease” (Br. 19)—are not inconsis-
tent with the position that the end-of-life care authorized by
the Oregon statute is a legitimate medical practice. More
importantly, the boundaries of legitimate medical practice
raise scientific and moral questions far too complex to be re-
solved by invoking the dictionary. “(T]he good physician is
not just a mechanic of the human body whose services have
no bearing on a person’s moral choices, but one who does
more than treat symptoms, one who ministers to the pa-
tient.... This idea of the physician as serving the whole
person is a source of the high value traditionally placed on
the medical relationship.” Glucksberg, 521 U.S. at 779
(Souter, J., concurring in the judgment). Nothing in either
the CSA or the regulation suggests otherwise, or intimates
that Oregon may not permit doctors, in the course of their
professional practice, to assist a terminally ill person to con-
trol the circumstances of his death."

'’ The Attorney General's contention (Br. 19-20) that the CSA’s leg-
islative history reveals an intention to prohibit the use of contrelled sub-
stances in connection with physician-assisted suicide is equally misguided.
The only reference to suicide in the House and Senate Reports occurs in
the context of a discussion concerning intentional and accidental over-
doses resulting from use contrary to or without professional advice, H.R.
Rep. No. 91-1444, at 35 (1970), not in accordance with it. Notably, in 1998
and again in 1999, Congress rejected legislation that would have expressly
extended the CSA to physician-assisted suicide. H.R. 4006, 105th Cong.
(1998) (“Lethal Drug Abuse Prevention Act of 1998”); H.R. 2260, 106th
Cong. (1999) (“Pain Relief Promotion Act of 1999”).

17

3. The Attorney General next contends that the CSA
must establish uniform standards for medical practice be-
cause “in the absence of a plain indication to the contrary,
... Congress when it enacts a statute is not making the ap-
plication of the federal act dependent on state law.” Pet. Br.
25 (quoting Mississippi Band of Choctaw Indians v. Holy-
field, 490 U.S. 30, 43 (1989)). But this “general assumption,”
Holyfield, 490 U.S. at 43, is simply inapplicable here, be-
cause the CSA contains several “plain indication[s] to the
contrary”: Congress defined “practitioner” in part by refer-
ence to state law; required that the Attorney General con-
sider state law in registering practitioners to dispense con-
trolled substances; and chose explicitly to adopt a uniform
federal standard concerning the treatment of drug addicts,
while declining to do so for any other area of medical prac-
tice.'' Congress clearly contemplated that the application of
the CSA in regulating physicians would vary from state to
state.

Neither United States v. 'foore nor United States v.
Oakland Cannabis Buyers’ Cooperative, 532 U.S. 483 (2001)
(discussed at Pet. Br. 28-32), supports a contrary conclusion.
Moore confirmed that the CSA “limit[s; a registered physi-
cian’s dispensing authority to the course of his ‘professional
practice.” 423 U.S. at 140. Because Moore “concede[d] in
his brief that he did not observe generally accepted medical
practices,” id. at 126, however, this Court had no occasion to
consider whether the CSA generally was intended to dis-
place state determinations of what constitutes “professional

'' It is not rare for Congress to make the application of a federal
statute dependent on state law, even without saying so expressly. See,
ey., BFP, 511 U.S. at 544 (holding that the term “reasonably equivalent
value” in the Bankruptcy Code’s fraudulent transfer provisions implicitly
incorporates state-law standards in the context of foreclosure sales);
Helvering v. Stuart, 317 U.S. 154, 161-162 (1942) (holding that the “neces-
sary implication” of federal tax statute is that conditions for taxing trust
assets depend on state property law, because “(t}he power to transfer or
distribute assets of a trust is essentially a matter of local law”).

18

practice.”"’ Indeed, as discussed above, Moore held that the
application of the CSA “turn[s] on whether the ‘transaction’
falls within or without legitimate channels” of distribution—
that is, whether the doctor was “act[ing] as a... ‘pusher’ not
as a physician.” /d. at 135, 143. Moore ,rovides no support
for the Attorney General’s notion that t... CSA sets sub-
stantive standards for medical practice where, as here, a
doctor is not acting as a drug dealer."’

Oakland Cannabis is similarly unhelpful to the Attor-
ney General. There, this Court held that, because marijuana
is a Schedule I drug with “no currently accepted medical
use,” 532 J.S. at 491 (quoting 21 U.S.C. § 812(b)(1)(B)),
“medical necessity is not a defense” to the CSA’s prohibition
of its manufacture and distribution, id. at 494. In other
words, Oakland Cannabis involved a state law that—unlike
the ODWDA—did create a “positive conflict,” 21 U.S.C.
§ 903, with the express terms of the CSA.

The Attorney General argues (Br. 29-30) that because
he could “reclassify the Schedule II substances typically
used by Oregon physicians to assist suicide to Schedule I if
the medical and scientific evidence warranted,” he must also
have the authority to override the States’ judgment regard-
ing which uses of Schedule II substances are medically
acceptable. This greater-power-includes-the-lesser logic is
flawed, because there is an important difference in the na-
ture of federal authority with respect to Schedule I drugs

'? Moreover, Moore dealt with the distribution of methadone osten-
sibly to treat heroin addicts, id. at 125-127—the one context in which the
CSA does seek to establish uniform federal standards for medical practice.

'’ The court of appeals decisions on which the Attorney General re-
lies (Br. 32) similarly involved doctors “not acting in good faith as . . . doc-
tor|s|, but simply pushing pills” for profit. United States v. Rosenberg,
515 F.2d 190, 197 (9th Cir. 1975). Although Rosenberg rejected the defen-
dant’s claim that the federal government could not constitutionally regu-
late medical practice and thus could not convict him absent a prior state
conviction, neither Rosenberg nor any of the other decisions suggests that
a doctor could act outside “the course of professional practice” by engag-
ing in a medical practice expressly authorized by state law.

19

and drugs on other schedules. A drug on Schedule I has
been federally determined to have “no currently accepted
medical use in treatment in the United States,” 21 U.S.C.
§ 812(b)(1)(B), and thus no state has the power to create or
approve such a use (as this Court held in Oakland Canna-
bis). Drugs on other schedules, however, have accepted
medical uses and may be dispensed to patients by practitio-
ners acting “in the course of professional practice.” /d.
§ 802(21). As discussed above, the CSA contemplates that
the Attorney General will defer to the States’ primary au-
thority to regulate the “professional practice” of medicine.

Indeed, even with respect to classification, the CSA ex-
pressly refuses to grant the Attorney General the authority
to make medical and scientific determinations—instead giv-
ing that power solely to the Secretary of Health and Human
Services. See id. § 811(b). This provision reflects Congress’s
common-sense recognition that, as a law enforcement offi-
cial, the Attorney General has no scientific or medical exper-
tise and thus should not be given the power to decide such
questions. The Attorney General’s construction of the
CSA—under which the statute expressly precludes him
from making medical determinations relating to classifica-
tion, yet implicitly grants him the power to set standards of
medical practice for the States—is simply implausible.

Ill. THE RULE OF LENITY COUNSELS AGAINST THE ATTORNEY
GENERAL’S INTERPRETATION OF THE CSA

Under the Attorney General’s novel and aggressive in-
terpretation of the CSA, a doctor commits a crime—and is
subject to criminal penalties, as well as the loss of federal
registration—when he prescribes controlled substances for a
medical purpose expressly authorized by Oregon law. As
demonstrated above, the CSA does not permit that con-
struction. Even if the CSA were unclear on this point, how-
ever, it is a “time-honored interpretive guideline that uncer-
tainty concerning the ambit of criminal statutes should be
resolved in favor of lenity.” United States v. Kozminski, 487
U.S. 931, 952 (1988). When confronted with “two rational
readings of a criminal statute, one harsher than the other,

20

we are to choose the harsher only when Congress has spo-
ken in clear and definite language.” McNally v. United
States, 483 U.S. 350, 359-360 (1987); see also, e.g., Crandon v.
United States, 494 U.S. 152, 158 (1990).

The rule of lenity—an application of the fundamental
principle nulla poena sine lege'*—is a means of effectuating
Congress’s intent. It presumes that, if Congress has not
clearly stated its decision to make a particular act a crime, it
likely has not carefully weighed the considerations that
would inform that decision. “{BJecause of the seriousness of
criminal penalties, and because criminal punishment usually
represents the moral condemnation of the community, legis-
latures”—and not courts or prosecutors—“should define
criminal activity.” Bass, 404 U.S. at 348; see also, e.g.,
Whalen v. United States, 445 U.S. 684, 689 (1980) (“[Within
our federal constitutional framework ... the power to define
criminal offenses ... resides wholly with the Congress.”).
By requiring Congress to speak “in clear and definite lan-
guage,” McNally, 483 U.S. at 360, the rule of lenity ensures
that Congress has in fact made a considered decision to
make the conduct at issue a crime. As shown above, see su-
pra Part II, the CSA contains no language authorizing the
Attorney General to regulate medical practice, much less to
make this particular instance of medical practice a federal
crime. The Directive thus improperly arrogates to the chief
federal prosecutor—contrary to the most basic principles
governing criminal law—the power to define a crime.

The rule of lenity plays a particularly vital role where,
as here, the government’s proposed expansive interpreta-
tion of a federal criminal statute would intrude on areas tra-
ditionally regulated by the States. In such a situation, it is
even less likely that Congress would have intended to create
a crime by implication. Thus, in Bass, this Court held that,

" See, e.g., Rogers v. Tennessee, 582 U.S. 451, 467-468 (2001) (Scalia,
J., dissenting) (noting that the maxim “dates from the ancient Greeks and
has been described as one of the most ‘widely held value-judgment|s} in
the entire history of human thought” (citation omitted)).

21

where the government’s interpretation of a criminal statute
would “significantly change[] the federal-state balance,” it is
especially appropriate to require that Congress have spoken
clearly before adopting that interpretation. Bass, 404 U.S.
at 349. Similarly, in Cleveland v. United States, the Court
adopted a narrow reading of the federal mail fraud statute
because a broader interpretation would “subject to federal
mail fraud prosecution a wide range of conduct traditionally
regulated by state and local authorities.” 531 U.S. 12, 24
(2000). And in McNally, the Court applied the rule of lenity
to construe the federal mail fraud statute not to reach a
scheme by state officials to deprive victims of an intangible
right to honest government, because that reading would in-
trude on a realm that is primarily the province of the States.
See 483 U.S. at 360.

The rule of lenity applies here even though the Attor-
ney General may choose not to pursue criminal prosecution.
See, e.g., Leocal v. Ashcroft, 125 8. Ct. 377 (2004). In Leocal,
this Court held that it was “constrained to interpret any am-
biguity in the statute in [the defendant’s] favor” because,
even though the statute was not being used in a criminal
context, “it has both criminal and noncriminal applications.
Because we must interpret the statute consistently, whether
we encounter its application in a criminal or noncriminal con-
text, the rule of lenity applies.” Jd. at 384 n.8; see also
Crandon, 494 U.S. at 158 (even for a civil penalty “set forth
in a criminal statute, it is appropriate to apply the rule of
lenity in resolving any ambiguity in the ambit of the stat-
ute’s coverage”); United States v. Thompson/Center Arms
Co., 504 U.S. 505, 517-518 (1992) (plurality opinion) (applying
rule of lenity to a tax statute construed in a civil setting be-
cause the statute also created criminal liability); id. at 519
(Scalia, J., concurring in the judgment) (same).

Because the Attorney General’s interpretation of the
CSA creates criminal liability where there is no evidence
that Congress intended to make the conduct at issue a crime

22

or to grant the Attorney General the power to do so, the rule
of lenity counsels that it should be rejected."”

IV. THE CSA SHOULD NoT BE READ TO PRECLUDE DEMOC-
RATIC DEBATE AND EXPLORATION OF DIFFERENT AP-
PROACHES BY THE STATES ON THE QUESTION OF PHYSI-
CIAN-ASSISTED SUICIDE

Both the presumption that Congress will not casually
intrude into an area traditionally the province of the States
and the rule of lenity ultimately derive from respect for the
democratic process in our Federal system. Those canons
give effect to the principle that certain questions are
particularly inappropriate for resolution by courts and
prosecutors, and that it is thus particularly critical to ensure
that Congress, as the most democratically accountable
branch, has carefully considered and clearly resolved them.

That is especially true in this case. The Directive pur-
ports to resolve the hotly disputed scientific, medical, and, at
bottom, moral question whether physician-assisted suicide
can ever be a part of legitimate medical practice. Less than
ten years ago, in Washington v. Glucksberg, this Court dis-
claimed the institutional competence to resolve that ques-

'S To be sure, as the Court observed in a footnote in Babbitt v. Sweet
Home Chapter of Communities for a Great Oregon, the rule of lenity does
not necessarily “provide the standard for reviewing facial challenges to
administrative regulations” in every case where “the governing statute
authorizes criminal enforcement.” 515 U.S. 687, 704 n.18 (1995). In other
words, Sweet Home observed that the rule of lenity will not always trump
Chevron deference, where such deference is appropriate. In that case,
unlike this one, Chevron deference was due because the agency had been
delegated, and had exercised, rulemaking authority to create the stan-
dards at issue. See id. at 703. As demonstrated below, see infra Part V,
no such de.erence is warranted here; the question is simply whether the
CSA makes it a crime, or empowers the Attorney General to make it a
crime, to prescribe drugs as authorized by the ODWDA. As a long-
established tool for determining congressional intent in criminal statutes
and a settled part of the interpretive background against whi:h Congress
legislates, the rule of lenity is obviously relevant to that inquiry.

23

tion, concluding that it should be answered through the de-
mocratic process. See 521 U.S. at 735.

As Glucksberg explained, “Americans today are increas-
ingly likely to die in institutions, from chronic illnesses. Pub-
lie concern and democratic action are therefore sharply fo-
cused on how best to protect dignity and independence at
the end of life ....” 521 U.S. at 716 (citation omitte/).
“Thus, the States are currently engaged in serious, thought-
ful examinations of physician-assisted suicide.” Jd. at 719.
The Court specifically noted Oregon’s choice to permit phy-
sician-assisted suicide “for competent, terminally ill adults.”
Id. at 717. And the Court’s ultimate decision not to recog-
nize a broad due process right to assistance in committing
suicide rested in part on its reluctance to cut off that democ-
ratic debate and exploration of different approaches among
the States: “Throughout the Nation, Americans are engaged
in an earnest and profound debate about the morality, legal-
ity, and practicality of physician-assisted suicide. Our hold-
ing permits this debate to continue, as it should in a democ-
ratic society.” Jd. at 735.

Justice O’Connor’s concurrence similarly noted: “As the
Court recognizes, States are presently undertaking exten-
sive and serious evaluation of physician-assisted suicide and
other related issues. ... In such circumstances, ‘the . . . chal-
lenging task of crafting appropriate procedures for safe-
guarding ... liberty interests is entrusted to the “labora-
tory” of the States ... in the first instance.” 521 U.S. at 737
(O’Connor, J., concurring) (citations omitted). And Justice
Souter expressly rested his concurrence in the judgment on
the proposition that the Court “should ... stay its hand to
allow reasonable legislative consideration” of the issue of
physician-assisted suicide. Jd. at 789 (Souter, J., concurring
in the judgment). He reasoned that only “experimentation
in some jurisdictions” can “confirm[] or discredit[{] the con-
cerns” about possible abuse of physician-assisted suicide,
and anticipated that the Court’s restraint would open the

24

door for “just such experimentation [to] be attempted in
some of the States.” /d. at 787-788 (citing the ODWDA)."°

These same considerations counsel strongly against in-
terpreting the CSA to permit an unelected executive official,
via administrative fiat, to foreclose all such exploration by
the States. In Justice Brandeis’ famous words:

To stay experimentation in things social and eco-
nomic is a grave responsibility. Denial of the right
to experiment may be fraught with serious conse-
quences to the nation. It is one of the happy inci-
dents of the federal system that a single courageous
state may, if its citizens choose, serve as a labora-
tory; and try novel social and economic experiments
without risk to the rest of the country.

New State Ice Co. v. Liebmann, 285 U.S. 262, 311 (1932)
(Brandeis, J., dissenting).

Only efforts like Oregon’s can resolve the “serious fac-
tual controversy” over the wisdom and feasibility of regu-
lated physician-assisted suicide—and, ultimately, the consti-
tutional question of the proper balance between the gov-
ernmental interest in protecting the disabled and vulnerable
and the individual’s interest in avoiding suffering and loss of
dignity at the end of life. Glucksberg, 521 U.S. at 786
(Souter, J., concurring in the judgment); see also id. at 737
(O’Connor, J., concurring). The Directive would eliminate
the only opportunity to learn, through experience with vari-
ous approaches to regulation and monitoring of physician-

© In Glucksberg, the Department of Justice advocated this cautious
approach, arguing that state legislatures, rather than the federal govern-
ment, should determine whether the terminally ill should be permitted to
request life-ending medication. See Br. of United States as Amicus Curiae
Supporting Petitioners, Washington v. Glucksberg (1996), 1996 WL
663185, at *10 (“Because terminal illness potentially affects all Americans
... there is every reason to believe that state legislatures will address the
urgent issues involved in this case in a fair and impartial way.”); id. at *27
n.3 (“States have begun to consider anew the issue of physician assisted
suicide, and there is no indication that the political processes are malfunc-
tioning.”) (citing Oregon’s approval of the ODWDA).

25

assisted suicide, whether opponents’ concerns about its use
are valid, and which approach best accommodates the deeply
important interests implicated. Oregon’s choice to permit
regulated physician-assisted suicide in limited circum-
stances, on the other hand, provides the chance to obtain ex-
perience and empirical data that can help answer those ques-
tions."

This Court’s task, of course, is not to evaluate the wis-
dom of Oregon’s choice, but to determine whether the CSA
precludes it from making that choice. That task of statutory
interpretation should be informed by a recognition of the
Directive’s effect. The Attorney General’s expansive con-

struction of his own power under the CSA would prema-

turely cut off democratic exploration and debate among the
States on the difficult questions surrounding end-of-life
care—and it would do so by making doctors’ compliance with
the ODWDA a federal crime. Basic principles of statutory
construction support the view that if Congress had intended
to take such a radical step—or to grant the Attorney Gen-
eral the authority to do so—it would have given a clearer
indication of its intent than the Attorney General can find in
the CSA. Because the Attorney General’s reading is not
authorized by the CSA, this Court should decline to adopt it,
and instead permit the debate over physician-assisted sui-
cide “to continue, as it should in a democratic society.”
Glucksberg, 521 U.S. at 735.

'’ The ODWDA requires detailed recordkeeping by physicians, see
Or. Rev. Stat. § 127.855, and requires that the Oregon Department of
Health Services prepare an annual report analyzing the state’s experience
with the ODWDA, see id. § 127.865. Oregon Health Services has thus far
issued seven such annual reports, which contain detailed information on
the demographic characteristics of the patients who requested prescrip-
tions under the ODWDA and the reasons for their choice. See Oregon
Dep’t of Human Services, Seventh Annual Report on Oregon’s Death with
Dignity Act (2005). These reports are a valuable source of information
about the experience of legalized, regulated physician-assisted suicide.

26

V. THE ATTORNEY GENERAL’S DIRECTIVE WARRANTS NO
DEFERENCE

Because, for all the reasons given above, the Directive is
not a permissible construction of the CSA, this Court need
not reach the Attorney General’s contention (Br. 21) that the
Directive deserves deference.'* Even if the Court were to
conclude that the Attorney General’s interpretation is not
precluded by the CSA, however, the Court should reject his
claim to deference—and, for the reasons above, should find
his reading of the statute unpersuasive.

Although the Attorney General now invokes Chevron
U.S.A. Inc. v. Natural Resources Defense Council, Inc., 467
U.S. 837 (1984), the Directive—an interpretive rule issued
without notice and comment, on a subject as to which the
Attorney General has no relevant expertise—is very far
from the type of agency pronouncement entitled to Chevron
deference."” Such deference is warranted only when “Con-
gress delegated authority to the agency generally to make
rules carrying the force of law,” such as by “adjudication or
notice-and-comment rulemaking,” and when “the agency in-
terpretation claiming deference was promulgated in the ex-
ercise of that authority.” United States v. Mead Corp., 533
U.S. 218, 226-227 (2001). “It is fair to assume generally that
Congress contemplates administrative action with the effect
of law when it provides for a relatively formal administra-
tive procedure tending to foster the fairness and delibera-
tion that should underlie a pronouncement of such force.”
Id. at 230.

That test is not met here. The Directive was issued not
only without notice and comment, but without any other

'* See MCI Telecommunications Corp. v. AT&T, 512 U.S. 218, 229
(1994) (“[A|n agency’s interpretation of a statute is not entitled to defer-
ence when it goes beyond the meaning that the statute can bear... .”).

Indeed, in the proceedings below, the Attorney General did not
even attempt to claim Chevron deference, instead arguing only for the

lesser standard of deference articulated in Skidmore v. Swift & Co., 323
U.S. 134 (1944). See Asheroft App. Br. 23-24.

27

procedural formalities that would “tend[ | to foster .. . fair-
ness and deliberation.” 533 U.S. at 230. The Directive relies
solely on a memorandum from the Office of Legal Counsel of
which Oregon was given no notice, and to which it was given
no opportunity to respond. Nor is there any indication in the
CSA that Congress intended to confer the kind of broad au-
thority that would warrant deference in the absence of no-
tice-and-comment procedures.” The Directive thus presents
“a case far removed not only from notice-and-comment proc-
ess, but from any other circumstances reasonably suggesting
that Congress” would have intended the Directive to enjoy
Chevron deference. /d. at 231.

Accordingly, the Directive should receive only whatever
deference is due under Skidmore v. Swift & Co., 323 U.S. 134
(1944). See, e.g., Mead, 533 U.S. at 234; Christensen v. Har-
ris County, 529 U.S. 576, 587 (2000). Under Skidmore, the
degree of deference afforded an agency pronouncement “de-
pend|s] upon the thoroughness evident in its consideration,
the validity of its reasoning, its consistency with earlier and
later pronouncements, and all those factors which give it
power to persuade.” 323 U.S. at 140.

The Directive fails when judged against these criteria.
First, the Directive bears no hallmarks of the kind of delib-
erative process that would entitle it to respect. The Attor-
ney General did not inform Oregon of his deliberations, so-
licit Oregon’s views, or take into account the empirical data
Oregon had collected in the four years that the ODWDA had
been in eff. =. Second, “[ajn agency interpretation ... which
conflicts with the agency’s earlier interpretation is ‘entitled
to considerably less deference’ than a consistently held

>’ By contrast, Congress specifically provided elaborate procedures
for altering the schedule of controlled substances—provisions that, as this
Court recognized in Touby, rendered tolerable the statute’s grant of au-
thority to the Attorney General, within the bounds set by the CSA, to
make rules that render criminal the possession and distribution of such
substances. See 500 U.S. at 166-167. The absence of similar procedures
here is compelling evidence that no such power was contemplated.

28

agency view.” INS v. Cardoza-Fonseca, 480 U.S. 421, 446
n.20 (1987) (citation omitted). Here, the Directive repre-
sents a recent and sharp reversal of course from the previ-
ous Attorney General’s views. See supra Part |. Third, the
Attorney General has no relevant scientific or medical ex-
pertise that would entitle him to deference on the question
whether physician-ase*: ied suicide is a legitimate medical
practice, see Mead Cor™ , 533 U.S. at 235—indeed, Congress
has expressly refused to give the Attorney General the
power to resolve scientific or medical questions under the
CSA, instead assigning that authority to the Secretary of
Health and Human Services, see 21 U.S.C. § 811(b).

The Attorney General erroneously contends, relying on
Auer v. Robbins, 519 U.S. 452 (1997), that he is entitled to a
particularly high degree of deference because the Directive
interprets both the CSA and the 1971 regulation. As the
Attorney General acknowledges (Br. 5, 17 n.6), however, the
regulation’s “legitimate medical purpose” standard merely
restates the statute’s “course of professional practice” re-
quirement. The question is therefore whether the Directive
is a permissible interpretation of the statute. It would make
no sense, in resolving that question, to give the Attorney
General greater deference than he would otherwise receive,
simply because of the existence of a regulation that echoes
the statutory standard.

As Aver itself makes clear, the primary justification for
special deference to an agency’s interpretation of its own
regulation is that, as the drafter of the regulation, the
agency is in the best position to know what it means. See
519 U.S. at 461 (finding that deference was due because the
concept at issue was “a creature of the Secretary’s own
regulations”); see also, e.g., Martin v. OSHRC, 499 U.S. 144,
152-153 (1991). Similarly, where the regulation being inter-
preted is part of “‘a complex and highly technical regulatory
program” established by the agency, the agency has special
relevant expertise entitling its views to respect. Thomas
Jefferson Univ. v. Shalala, 512 U.S. 504, 512 (1994) (ci*stion
omitted). Neither justification for special deference has any

29

force here, where the regulation merely restates the statu-
tory standard, and Congress has refused to give the Attor-
ney General the power to resolve medical and scientific
questions of the kind addressed by the Directive.*'

Finally, whatever standard is applied, the very nature
of the question that the Directive purports to resolve coun-
sels strongly against granting the Attorney General the def-
erence he seeks. As the Court has explained, “we must be
guided to a degree by common sense as to the manner in
which Congress is likely to delegate a policy decision of
[great] economic and political magnitude to an administra-
tive agency.” FDA v. Brown & Williamson Tobacco Corp.,
529 U.S. 120, 133 (2000) (holding that the Food, Drug, and
Cosmetic Act did not grant the FDA the authority to regu-
late tobacco products). The more important and politically
fraught the question, the less likely it is that Congress would
grant an agency the power to resolve it without making the
delegation of authority clear. See id.; see also MCI, 512 U.S.
at 231; Kent v. Dulles, 357 U.S. 116, 129 (1958). Put another
way, “Congress does not alter the fundamental details of a
regulatory scheme in vague terms or ancillary provisions—it
does not, one might say, hide elephants in mouseholes.”
Whitman v. American Trucking Ass’ns, 531 U.S. 457, 468
(2001) (holding that, for the Clean Air Act to grant the EPA
authority to consider costs in setting air quality standards,
the “textual commitment must be a clear one” and finding no

*' As several Justices have noted, application of the Aver rule may in
some cases “disserve|| the very purpose behind the delegation of lawmak-
ing power to administrative agencies” by giving the agency an incentive
to promulgate vague regulations and supply the necessary detail through
procedures that lack the constraints imposed by notice-and-comment
rulemaking. Thomas Jefferson Univ., 512 U.S. at 525 (Thomas, J., dis-
senting, joined by Stevens, O’Connor, and Ginsburg, JJ.); see generally
John F. Manning, Constitutional Structure and Judicial Deference to
Agency Interpretations of Agency Rules, 96 Colum. L. Rev. 612, 618, 654-
660 (1996). That concern is even more powerful here, where the interpre-
tation of the regulation criminalizes conduct not clearly made a crime by
either the statute or the regulation.

30

such clear delegation of authority). That is particularly true
where, as here, the agency’s assertion of power “alters the
federal-state framework by permitting federal encroach-
ment upon a traditional state power.” Solid Waste, 531 U.S.
at 173 (refusing to grant Chevron deference to an adminis-
trative interpretation of a statute that altered the federal-
state balance).

These principles should govern here. Physician-assisted
suicide is precisely the kind of important and divisive politi-
cal question that Congress does not delegate to an adminis-
trative agency by implication. Yet the Directive arrogates
to a single unelected executive official the authority to de-
cide that question and to cut short the democratic debate on
end-of-life care among the States. Only a much clearer
statement would justify the conclusion that Congress in-
tended to take such a momentous step. Because the CSA
does not grant the Attorney General the power to resolve
the profound medical, political, and moral questions posed by
physician-assisted suicide, the Directive should be rejected.

CONCLUSION

The judgment of the United States Court of Appeals for
the Ninth Circuit should be affirmed.

Respectfully submitted,

DAVID W. OGDEN
Counsel of Record
PAUL R.Q. WOLFSON
DAVID S. MENDEL
DANIELLE SPINELLI
HEATHER ELLIOTT
NORA FREEMAN ENGSTROM
WILMER CUTLER PICKERING
HALE AND DORR LLP
2445 M Street, N.W.
Washington, DC 20037
(202) 663-6000

JULY 2005

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/brief%3Amicro_IA40385016_0051%3A34. Public record. Not legal advice.
